The research was a collaborative work led by Drew Weissman, MD, PhD, of the Division of Infectious Diseases and Katalin Karikó, PhD, of the Department of Neurosurgery. The investigators published their findings in the August issue of Immunity. "We think this study will open a new area of research in understanding how our immune systems protect us," says Weissman.
"One application of our findings is that scientists will be able to design better therapeutic RNAs, including anti-sense or small-interfering RNAs, for treating diseases such as cancer and single-gene genetic diseases," says Karikó.
RNA is the genetic material that programs cells to make proteins from DNA's blueprint and specifies which proteins should be made. There are many types of RNA in the cells of mammals, such as transfer RNA, ribosomal RNA, messenger RNA, and all of them have specific types of chemical tags, or modifications. In contrast, RNAs from bacteria have fewer or no modifications.
Another type of RNA in mammalian cells is found in mitochondria, the powerhouses of cells. Mitochondrial RNA is thought to have originated from bacteria millions of years ago. Similar to RNA from bacteria, mitochondrial RNA has fewer chemical tags. It is the absence of modifications that causes RNA from bacteria and mitochondria to activate the immune response. The researchers suggest that these modifications have evolved in animals as one of the ways for the innate immune system to discriminate self from non-self.
When a tissue is damaged by injury, infection, or inflammation, cells release their mitochondrial RNA. This RNA acts as a signal to the immune system to recognize the damage and help defend and repair the tissue.
Conversely, the presence of the modifications on the other types of RNA does not activate an immune response and thus allows the innate immune system to discriminate self from non-self. "We showed that special proteins on the surface of immune cells, called Toll-like receptors, are instrumental in recognizing bacterial and mitochondrial RNA," explains Weissman. The amount of modification on the RNA is important because as little as one or two tags per RNA molecule could prevent or suppress the immune reaction.
The authors concluded that the potential of RNA to activate immunity seems to be inversely correlated with the extent of its chemical modification and may explain why some viral RNA that is overly modified evades immune surveillance. The authors plan to investigate whether longer RNAs with specific tags will be useful for delivering therapeutic molecules to diseased cells.
This study was funded by the National Institutes of Health. Co-authors are Michael Buckstein and Houping Ni, both from Penn.
This release can also be found at: www.uphs.upenn.edu/news.
PENN Medicine is a $2.7 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System includes three owned hospitals [Hospital of the University of Pennsylvania, which is consistently ranked one of the nation's few "Honor Roll" hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.
Journal
Immunity